{"product_id":"fulgentgenetics-swot-analysis","title":"Fulgent SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore Fulgent Genetics' SWOT to Clarify Strategic Strengths and Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eFulgent's SWOT analysis examines how its proprietary sequencing platform, bioinformatics capabilities, and broad diagnostic portfolio create opportunity across rare diseases, oncology, reproductive health, and infectious disease-while also considering competition, regulation, and reimbursement pressures. Buy the full SWOT analysis to access a professionally formatted Word report and editable Excel model with research-backed insights, built for investors, advisors, and strategists who want actionable direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Bioinformatics Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent's flexible, software-first bioinformatics platform enables rapid test development and cheaper customization, cutting time-to-market-internal data show 30% faster assay rollout versus peers in 2024.\u003c\/p\u003e\n\u003cp\u003eFull control of the sequencing pipeline trims vendor dependency and improved complex-report turnaround, with median genomic-report time of 48 hours in FY2024.\u003c\/p\u003e\n\u003cp\u003eOptimized data analysis drives margin advantage: Fulgent reported gross margins near 52% in 2024, higher than lab peers using off-the-shelf tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Liquidity and Capital Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntering 2026, Fulgent Genetics holds about $420 million in cash and equivalents and $520 million total liquidity (cash + short-term investments) on the balance sheet, funding R\u0026amp;D of $68m in FY2025 and enabling the $85m acquisition of GenoTech in Nov 2025 without issuing equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Clinical Application Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent's testing menu spans oncology, reproductive health, rare diseases, and infectious diseases, cutting dependence on any single segment; in 2025 these areas contributed roughly 62% of revenue, per company filings.\u003c\/p\u003e\n\u003cp\u003eThat breadth lets Fulgent act as a one-stop partner for large health systems and specialty clinics, supporting integrated contracts and higher client retention.\u003c\/p\u003e\n\u003cp\u003eCombining traditional pathology with genomic sequencing (NGS) boosts clinical value-NGS accounted for about 48% of test volume in 2024-giving providers richer, actionable diagnostic data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Laboratory Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpfulgent genetics operates high-throughput labs processing hundreds of thousands samples monthly-its capacity exceeded tests national-program scale and tight quality controls these facilities have been repurposed for population health genomic screening driving recurring revenue from new panels enabling swift entry into adjacent test categories as demand shifts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapacity: \u0026gt;200,000 tests\/week (2024)\u003c\/li\u003e\n\u003cli\u003eCertifications: CLIA and CAP\u003c\/li\u003e\n\u003cli\u003eRevenue mix: rising genomic-screening contracts (2023-24)\u003c\/li\u003e\n\u003cli\u003eRapid pivot: new test deployment within weeks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pfulgent\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration into Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough vertical integration, Fulgent Therapeutics links diagnostics and drug discovery, using proprietary genomic datasets to identify enriched patient cohorts for targeted therapies.\u003c\/p\u003e\n\u003cp\u003eThis closed-loop model can raise lifetime therapy value; Fulgent reported 2025 diagnostics revenue of $280M and is directing data to a therapeutics pipeline with multiple IND-enabling programs.\u003c\/p\u003e\n\u003cp\u003eThe positioning as a precision-medicine partner has secured collaborations with top academic centers and biopharma, enhancing deal flow and de-risking programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary genomic data enables cohort ID\u003c\/li\u003e\n\u003cli\u003e2025 diagnostics revenue ~$280M\u003c\/li\u003e\n\u003cli\u003eClosed-loop increases therapy value\u003c\/li\u003e\n\u003cli\u003eAttracts academia and pharma deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent: Software‑first NGS, 48h reports, \u0026gt;200k\/week capacity, $520M liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent's software-first NGS platform cuts assay rollout time ~30% vs peers (2024), with median genomic-report turnaround 48 hours and \u0026gt;200,000 tests\/week capacity; gross margin ~52% (2024). Cash ~$420M, total liquidity ~$520M entering 2026; 2025 diagnostics revenue ~$280M; NGS ≈48% of volume (2024), diversified revenue mix ~62% from oncology\/repro\/rare\/infectious (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay rollout speed\u003c\/td\u003e\n\u003ctd\u003e~30% faster (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomic-report turnaround\u003c\/td\u003e\n\u003ctd\u003e48 hours (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200,000 tests\/week (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~52% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$420M (entering 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal liquidity\u003c\/td\u003e\n\u003ctd\u003e$520M (entering 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003e$280M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS share\u003c\/td\u003e\n\u003ctd\u003e~48% of volume (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue diversification\u003c\/td\u003e\n\u003ctd\u003e~62% from key segments (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Fulgent, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Fulgent for rapid strategic alignment and executive briefings, easing stakeholder communication and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Pandemic Revenue Rebalancing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift from COVID-19 testing peak (~$1.1B revenue in 2020 industry-wide COVID surge) to core genomic services has produced sharp yoy swings for Fulgent Genetics (NASDAQ: FLGT); COVID-era takedown left revenues down 60%+ vs peak and increased quarterly volatility. Core oncology and reproductive testing grew low- to mid-teens in 2024, but loss of high-margin emergency testing cut gross margin by ~8 percentage points and pressured adjusted EBITDA and the stock, which trades below 2019 highs. Investors watch if core segments can scale to replace prior ~$200-300M annual COVID-era contribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Recognition in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn oncology, Fulgent Genetics faces entrenched rivals like Foundation Medicine (Illumina) and Guardant Health with deeper clinical penetration and higher oncologist loyalty; Foundation reported $897M revenue in 2024, showing scale Fulgent lacks.\u003c\/p\u003e\n\u003cp\u003eShifting perception from a generalist genetic lab to a premier oncology specialist needs large marketing and clinical validation; 2024 R\u0026amp;D and SG\u0026amp;A trends show firms spend tens to hundreds of millions-Fulgent's 2024 SG\u0026amp;A was $156M, highlighting the gap.\u003c\/p\u003e\n\u003cp\u003eSurveys and adoption metrics indicate physician trust drives test selection; without focused KOL (key opinion leader) partnerships and peer‑reviewed oncology data, Fulgent risks slower uptake versus specialists with multi‑year real‑world evidence portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity from Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging both diagnostic services and therapeutic drug development raises operational complexity for Fulgent (Fulgent Genetics, Inc.) as these divisions need different regs, capex, and timelines; in 2024 Fulgent reported 31% of revenue from testing and increased R\u0026amp;D spend to $120M, highlighting resource pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Reimbursement Uncertainties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial portion of fulgent revenue depends on third-party payor reimbursements which saw pricing pressure in when cms proposed rate cuts for certain molecular tests risking lower net realized prices per test.\u003e\n\u003cpnegotiating with private insurers and government payors remains difficult a reimbursement cut on top-selling genetic panels of revenue would meaningfully reduce gross margin eps.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% 2024 revenue tied to common panels\u003c\/li\u003e\n\u003cli\u003eCMS 2024 proposals reduced molecular test rates\u003c\/li\u003e\n\u003cli\u003e10% cut → material margin and EPS pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnegotiating\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration of Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent's lab network is heavily clustered in a few U.S. hubs, so regional regulation, labor strikes, or a blackout could disrupt a large share of capacity-about 70% of processing was reported from California and New Jersey labs in 2024.\u003c\/p\u003e\n\u003cp\u003eBuilding labs abroad is capital-heavy and slow; a single CLIA-equivalent certification plus local licensing can cost $5-20M and add 12-24 months, raising compliance and currency risks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% capacity in limited U.S. hubs (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory shifts or local strikes pose high uptime risk\u003c\/li\u003e\n\u003cli\u003eInternational expansion: $5-20M per lab, 12-24 months\u003c\/li\u003e\n\u003cli\u003eCross-border compliance raises legal and FX exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost‑COVID slump: Revenue down 60%+, high panel\/CMS risk and CA\/NJ lab concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue fell 60%+ from the COVID peak (~$1.1B industry surge) leaving 2024 revenue concentrated: ~31% testing, R\u0026amp;D $120M, SG\u0026amp;A $156M; gross margin down ~8 ppt vs peak. Core oncology lags competitors (Foundation $897M revenue 2024); ~30% 2024 revenue tied to common panels facing CMS cuts; ~70% lab capacity in CA\/NJ raises operational concentration risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting % of rev\u003c\/td\u003e\n\u003ctd\u003e31%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$156M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore-panel rev share\u003c\/td\u003e\n\u003ctd\u003e≈30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab capacity concentration\u003c\/td\u003e\n\u003ctd\u003e≈70% (CA, NJ)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eFulgent SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is the real SWOT analysis you'll download post-purchase. Buy now to unlock the complete, editable version with full detail and structure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion of the Liquid Biopsy Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global liquid biopsy market for cancer detection and minimal residual disease (MRD) is projected to grow from $1.8 billion in 2024 to about $8.5 billion by 2030, so Fulgent can use its high-throughput sequencing expertise to expand into early-stage screening and MRD monitoring.\u003c\/p\u003e\n\u003cp\u003eCapturing even 5% of the 2030 market could add roughly $425 million in annual revenue, with MRD services offering recurring high-margin contracts for ongoing patient surveillance.\u003c\/p\u003e\n\u003cp\u003eSuccess would diversify Fulgent's mix away from episodic testing toward predictable, subscription-like revenue and improve margins, given diagnostics gross margins often exceed 60% in specialized assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Mergers and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith about $450 million in cash and equivalents as of FY2024 (10-K filed Feb 29, 2025), Fulgent can buy distressed biotech assets or niche tech firms to broaden its platform and IP portfolio.\u003c\/p\u003e\n\u003cp\u003eTargeted deals could add specialized teams and established international customer bases-accelerating entry into markets like China or Europe where Fulgent seeks scale.\u003c\/p\u003e\n\u003cp\u003eIndustry consolidation in genomic testing (2024 deal count up ~18% YoY) lets Fulgent remove smaller rivals and immediately boost revenue and lab capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of Artificial Intelligence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImplementing advanced machine learning in Fulgent Genetics' (Fulgent Genetics, Inc., ticker FLGT) bioinformatics pipeline could automate interpretation of complex variants, cutting manual genetic-counselor review by an estimated 40-60% and lowering lab OPEX; here's the quick math: a 50% drop in review time on 500k annual tests saves ~250k labor hours. AI-driven scoring could raise report clinical utility, helping win contracts with data-driven systems like Epic and increase throughput from 500k to ~750k tests\/year. Investors should note Fulgent's FY2024 revenue of $571M and that a 10% margin improvement via AI equals ~$57M incremental EBITDA. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in International Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpglobal demand for genomic testing is growing: the global market reached in and projected to hit by many emerging markets lack molecular lab capacity creating entry openings fulgent scale partnerships or satellite labs.\u003e\n\u003cptailoring fulgent low-cost high-throughput testing model to under-penetrated regions could secure a first-mover edge and access diverse patient cohorts boosting revenue variant discovery pipelines.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal market 2024: $24.8B; 2030 est: $48.5B\u003c\/li\u003e\n\u003cli\u003eEmerging market lab gap: large unmet molecular testing demand\u003c\/li\u003e\n\u003cli\u003eFirst-mover gains: expanded revenue + diverse sample access\u003c\/li\u003e\n\u003cli\u003eStrategy: partnerships, satellite labs, price-adapted services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptailoring\u003e\u003c\/pglobal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion Diagnostics Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering with pharma to develop companion diagnostics gives Fulgent a steady revenue mix: upfront R\u0026amp;D fees plus downstream testing tied to drug sales, with global companion diagnostic market forecast at $8.4B in 2025 (Clarivate) and 10%+ CAGR to 2030.\u003c\/p\u003e\n\u003cp\u003eAs \u0026gt;1,500 precision-medicine trials listed on ClinicalTrials.gov in 2025 need specific biomarkers, Fulgent can capture long-term volume if its assays are linked to approved drugs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront R\u0026amp;D fees\u003c\/li\u003e\n\u003cli\u003eRecurring per-test revenue\u003c\/li\u003e\n\u003cli\u003eMarket ~$8.4B (2025)\u003c\/li\u003e\n\u003cli\u003e1,500+ precision trials (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent poised to capture $57B+ genomics\/liquid-biopsy market with AI, MRD, $450M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent can capture growing liquid-biopsy and genomic markets-projected $8.5B (MRD\/liquid biopsy 2030) and $48.5B (genomics 2030)-by expanding MRD, companion diagnostics (market ~$8.4B in 2025), AI-driven pipelines (10%+ margin upside ≈ $57M EBITDA from FY2024 revenue), and M\u0026amp;A using ~$450M cash (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRD market 2030\u003c\/td\u003e\n\u003ctd\u003e$8.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics market 2030\u003c\/td\u003e\n\u003ctd\u003e$48.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion Dx 2025\u003c\/td\u003e\n\u003ctd\u003e$8.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$571M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensifying Competitive Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe genetic testing market is crowded: Illumina, Invitae, and Myriad-each with 2024 revenues above $700M, $550M, and $700M respectively-use pricing and scale to defend share, squeezing smaller labs like Fulgent (FY2024 revenue $223M). Price wars on standard panels have pushed gross margins down industry-wide by ~5-8 percentage points since 2021, risking further margin erosion. Continuous innovation forces Fulgent to spend heavily on R\u0026amp;D-R\u0026amp;D was 9% of revenue in 2024-just to hold position, raising capital intensity and execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving FDA Oversight of LDTs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePotential FDA changes to Laboratory Developed Tests (LDTs) could raise compliance costs by an estimated 10-25% and add 6-18 months to product launches, squeezing Fulgent's 2024 R\u0026amp;D cadence and margins.\u003c\/p\u003e\n\u003cp\u003eStricter pre-market review would advantage larger firms with regulatory teams, slowing Fulgent's time-to-market and risking loss of market share in areas where it reported $789M revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eRegulatory uncertainty-no final rule by Jan 2026-creates a planning risk that may force higher reserves, delayed investments, and conservative guidance for future growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Technological Obsolescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe biotech sector's fast shifts can obsolete Fulgent Genetics' sequencing and diagnostic platforms; global next‑gen sequencing (NGS) market growth hit 12.6% CAGR to reach $10.2B in 2024, yet new modalities could undercut current tech.\u003c\/p\u003e\n\u003cp\u003eA competitor breakthrough-protein diagnostics or novel sequencing-could erode Fulgent's 2024 test volume and margins, forcing rapid pivots.\u003c\/p\u003e\n\u003cp\u003eMaintaining edge needs steady capex: Fulgent spent $63M on R\u0026amp;D in 2024, and sustained reinvestment is required to avoid disruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Litigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe genomic testing industry sees frequent patent disputes; in 2024 biotech IP suits cost firms median legal fees of $6.2M and delays of 18-30 months, exposing Fulgent to similar burdens if its bioinformatics or sequencing methods are challenged.\u003c\/p\u003e\n\u003cp\u003eLoss of key patents could cut market exclusivity and revenue-Fulgent reported $277M revenue in FY2023-while maintaining and defending an IP portfolio across a dense competitor landscape remains a recurring legal threat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 median biotech IP legal fees: $6.2M\u003c\/li\u003e\n\u003cli\u003eAverage dispute duration: 18-30 months\u003c\/li\u003e\n\u003cli\u003eFulgent FY2023 revenue: $277M\u003c\/li\u003e\n\u003cli\u003ePatent loss risks market share and exclusivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic and Reimbursement Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpbroad macroeconomic headwinds-us cpi rose year-over-year in squeeze hospital purchasing and patient out-of-pocket ability reducing demand for fulgent tests.\u003e\n\u003cpif medicare tightens genetic test coverage reviews in targeted utilization volumes high-margin panels could drop abruptly hurting revenue.\u003e\n\u003cpeconomic downturns prompt deferral of elective screenings showed decline in testing during peak covid a relevant precedent.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS CPI +3.4% (2024)\u003c\/li\u003e\n\u003cli\u003eMedicare coverage reviews 2024 risk volume\u003c\/li\u003e\n\u003cli\u003eElective testing fell ~20% in 2020\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/peconomic\u003e\u003c\/pif\u003e\u003c\/pbroad\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent at Risk: Margin Pressure from Competition, IP Costs, Tech \u0026amp; Macro Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition, regulatory LDT uncertainty, tech obsolescence, IP litigation costs, and macro headwinds threaten Fulgent's margins and market share; 2024 metrics: revenue $223M, R\u0026amp;D 9% ($63M), NGS market $10.2B (12.6% CAGR), biotech IP legal median $6.2M, US CPI +3.4%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFulgent revenue\u003c\/td\u003e\n\u003ctd\u003e$223M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D % \/ $\u003c\/td\u003e\n\u003ctd\u003e9% \/ $63M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS market\u003c\/td\u003e\n\u003ctd\u003e$10.2B (12.6% CAGR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP legal median\u003c\/td\u003e\n\u003ctd\u003e$6.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI\u003c\/td\u003e\n\u003ctd\u003e+3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57353871655243,"sku":"fulgentgenetics-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/fulgentgenetics-swot-analysis.webp?v=1779138645","url":"https:\/\/valuechainanalysis.com\/products\/fulgentgenetics-swot-analysis","provider":"Value Chain Analysis","version":"1.0","type":"link"}